Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beno

Showing results (351-360 of 383) with videos related to

Pageof 39
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Journal of Medicinal Chemistry|January 18, 2018
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral BioavailabilityJohn T Randolph, A Chris Krueger, Pamela L Donner, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B InhibitorsKap-Sun Yeung, Brett R Beno, Kathy Mosure, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Annals of Surgery|July 16, 2025
Validation of Quality Indicators for Pediatric Trauma CareLynne Moore, Natalie L Yanchar, Suzanne Beno, et al.
Journal of Medicinal Chemistry|April 15, 2018
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)Rolf Wagner, John T Randolph, Sachin V Patel, et al.
ACS Medicinal Chemistry Letters|June 22, 2016
Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral ActivityAlicia Regueiro-Ren, Zheng Liu, Yan Chen, et al.
JAMA Pediatrics|March 31, 2025
Evidence-Informed Quality Indicators for Pediatric Trauma CareLynne Moore, Natalie L Yanchar, Pier-Alexandre Tardif, et al.
Journal of Medicinal Chemistry|July 21, 2006
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonistsZhili Xin, Michael D Serby, Hongyu Zhao, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TBSimon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
Pageof 39

Showing results (351-360 of 383) with videos related to

Sort By:
Pageof 39
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Journal of Medicinal Chemistry|January 18, 2018
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral BioavailabilityJohn T Randolph, A Chris Krueger, Pamela L Donner, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B InhibitorsKap-Sun Yeung, Brett R Beno, Kathy Mosure, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Annals of Surgery|July 16, 2025
Validation of Quality Indicators for Pediatric Trauma CareLynne Moore, Natalie L Yanchar, Suzanne Beno, et al.
Journal of Medicinal Chemistry|April 15, 2018
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)Rolf Wagner, John T Randolph, Sachin V Patel, et al.
ACS Medicinal Chemistry Letters|June 22, 2016
Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral ActivityAlicia Regueiro-Ren, Zheng Liu, Yan Chen, et al.
JAMA Pediatrics|March 31, 2025
Evidence-Informed Quality Indicators for Pediatric Trauma CareLynne Moore, Natalie L Yanchar, Pier-Alexandre Tardif, et al.
Journal of Medicinal Chemistry|July 21, 2006
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonistsZhili Xin, Michael D Serby, Hongyu Zhao, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TBSimon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
Pageof 39